Anti-VISTA structures and their use
JP7874927B2Active Publication Date: 2026-06-17DYNAMICURE BIOTECHNOLOGY LLC
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- DYNAMICURE BIOTECHNOLOGY LLC
- Filing Date
- 2022-03-04
- Publication Date
- 2026-06-17
AI Technical Summary
Technical Problem
Current treatments for autoimmune diseases and dysregulated immune systems, such as graft-versus-host disease and lupus, are inadequate in modulating VISTA signaling to effectively manage these conditions.
Method used
Development of anti-VISTA constructs, including antibodies and their fragments, that compete for the VISTA binding epitope and activate its downstream signaling pathway, providing therapeutic options for autoimmune diseases and immune dysregulation.
Benefits of technology
The anti-VISTA constructs effectively modulate immune responses, offering potential treatments for autoimmune diseases like lupus and graft-versus-host disease by activating VISTA signaling, thereby improving treatment outcomes.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 0007874927000014 
Figure 0007874927000015 
Figure 0007874927000016
Abstract
The present application provides anti-VISTA constructs (e.g., anti-VISTA antibodies) that bind to VISTA, nucleic acid molecules encoding the amino acid sequence of anti-VISTA, vectors comprising the nucleic acid molecules, host cells comprising the vectors, methods of preparing the anti-VISTA constructs, pharmaceutical compositions comprising the anti-VISTA constructs, and methods of using the anti-VISTA constructs or compositions. Exemplary anti-VISTA constructs include agonist antibodies capable of binding to and activating VISTA.
Need to check novelty before this filing date? Find Prior Art